chaofann/E+ via Getty Images Vir Biotechnology ( NASDAQ: VIR ) traded higher premarket Wednesday after announcing that its investigational therapy tobevibart developed with Xencor ( XNCR ) showed early signs of efficacy in a Phase 2 trial for people infected with chronic hepatitis delta virus. Citing initial data from its SOLSTICE trial, California-based VIR said tobevibart as a single agent and combined with RNA-interfering therapy, elebsiran led to "high rates of virologic response" at weeks 12 and 24. Additionally, 50% of subjects managed to normalize their ALT enzymes, and there were no serious adverse events, the company announced.
The safety update was based on 48-week data from six subjects received tobevibart as monotherapy and in combination with Alnylam ( ALNY )-partnered elebsiran. Vir ( VIR ) disclosed the data ahead of a presentation it plans to conduct at a European medical event on liver studies over the weekend. More on Vir Biotechnology Vir Biotechnology Provides Some Hope For Its Beleaguered Shareholders Vir Biotechnology, Inc.
(VIR) Q1 2024 Earnings Call Transcript Vir Biotechnology GAAP EPS of -$0.48 beats by $0.59, revenue of $56.
38M beats by $44.67M Seeking Alpha’s Quant Rating on Vir Biotechnology Historical earnings data for Vir Biotechnology.
